Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells

(1) Background: TP53 deficiency remains a major adverse event in Multiple Myeloma (MM) despite therapeutic progresses. As it is not possible to target TP53 deficiency with pharmacological agents, we explored the possibility of activating another p53 family member, p73, which has not been well studie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Mol Sci
Autors principals: Gillardin, Pierre-Samuel, Descamps, Géraldine, Maiga, Sophie, Tessoulin, Benoit, Djamai, Hanane, Lucani, Benedetta, Chiron, David, Moreau, Philippe, Le Gouill, Steven, Amiot, Martine, Pellat-Deceunynck, Catherine, Moreau-Aubry, Agnès
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2017
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5795990/
https://ncbi.nlm.nih.gov/pubmed/29295500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19010040
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars